Compare EPAM Systems Inc (EPAM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Zoetis Inc — how do they compare? EPAM Systems Inc trades at $99.88 (market cap $5.15B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 6× EPAM Systems Inc's market cap, and Zoetis Inc pays a 2.81% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | ZTS | |
|---|---|---|
Market Cap | $5.15B | $31.14B |
Sector | Technology | Health |
52-Week High | $221.40 | $156.76 |
52-Week Low | $76.04 | $71.91 |
Enterprise Value | $4.52B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $100.29, up 3.0% with recent earnings beats but faces technical bearish signals. The company reported strong Q2 2026 results with EPS of $3.38 beating estimates, though revenue guidance was lowered due to North American softness. Valuation appears attractive with P/E of 13.55 and P/S of 0.97, while profitability metrics remain solid with 7.15% net margin.
The stock presents a value opportunity with analyst consensus target of $117.27 (17% upside), but faces near-term headwinds from reduced revenue guidance and technical weakness. Key risks include slowing demand in core markets, while the OpenAI partnership offers AI growth potential. Institutional sentiment remains positive with 65% buy ratings.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
